Skip to content

Study · Non-randomized trial · 2019

4 results

Efficacy of Neuroprotective Drugs in Acute Ischemic Stroke: Is It Helpful?

Mehta A, Mahale R, Buddaraju K, Javali M, Acharya P, Srinivasa R

Journal of neurosciences in rural practice1 Oct 2019Cited by 27 (Europe PMC)

PMID31831974 (opens in a new tab)PMCIDPMC6906097 (opens in a new tab)DOI10.1055/s-0039-1700790 (opens in a new tab)PepBankPUB-31831974
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with acute MCA territory ischemic stroke, Cerebrolysin significantly lowered mean NIHSS scores compared with placebo at day 11.

    In plain wordsIn patients with acute ischemic stroke, Cerebrolysin lowered stroke severity scores more than placebo at day 11.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNIHSS score at day 11
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results The mean NIHSS score was significantly lesser at day 11 and after 90 days in citicoline, edaravone, and cerebrolysin group in comparison with placebo.
    2 context sentences
    Summary · context
    Materials and Methods This was a prospective, single center, single-blinded, and hospital-based study.
    Summary · context
    One hundred patients with MCA territory AIS with 20 patients in each group including control group were included.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with acute MCA territory ischemic stroke, Cerebrolysin significantly lowered mean NIHSS scores compared with placebo after 90 days.

    In plain wordsIn patients with acute ischemic stroke, Cerebrolysin lowered stroke severity scores more than placebo after 90 days.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNIHSS score after 90 days
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results The mean NIHSS score was significantly lesser at day 11 and after 90 days in citicoline, edaravone, and cerebrolysin group in comparison with placebo.
    2 context sentences
    Summary · context
    Materials and Methods This was a prospective, single center, single-blinded, and hospital-based study.
    Summary · context
    One hundred patients with MCA territory AIS with 20 patients in each group including control group were included.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with acute MCA territory ischemic stroke, Cerebrolysin significantly increased mean Barthel index scores compared with placebo at day 11.

    In plain wordsIn patients with acute ischemic stroke, Cerebrolysin improved Barthel index scores more than placebo at day 11.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBarthel index at day 11
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similarly, the mean BI score was significantly higher at day 11 and after 90 days in citicoline, edaravone, and cerebrolysin group in comparison with placebo.
    2 context sentences
    Summary · context
    Materials and Methods This was a prospective, single center, single-blinded, and hospital-based study.
    Summary · context
    One hundred patients with MCA territory AIS with 20 patients in each group including control group were included.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with acute MCA territory ischemic stroke, Cerebrolysin significantly increased mean Barthel index scores compared with placebo after 90 days.

    In plain wordsIn patients with acute ischemic stroke, Cerebrolysin improved Barthel index scores more than placebo after 90 days.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBarthel index after 90 days
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similarly, the mean BI score was significantly higher at day 11 and after 90 days in citicoline, edaravone, and cerebrolysin group in comparison with placebo.
    2 context sentences
    Summary · context
    Materials and Methods This was a prospective, single center, single-blinded, and hospital-based study.
    Summary · context
    One hundred patients with MCA territory AIS with 20 patients in each group including control group were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.